Wider Christian, Lincoln Sarah J, Heckman Michael G, Diehl Nancy N, Stone Jeremy T, Haugarvoll Kristoffer, Aasly Jan O, Gibson J Mark, Lynch Timothy, Rajput Alex, Rajput Michele L, Uitti Ryan J, Wszolek Zbigniew K, Farrer Matthew J, Ross Owen A
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Neurosci Lett. 2009 Mar 27;453(1):9-11. doi: 10.1016/j.neulet.2009.02.009. Epub 2009 Feb 10.
Attempts at replicating the first genome-wide association study (GWAS) in Parkinson's disease (PD) have not successfully identified genetic risk factors. The present study reevaluates data from the first GWAS and focuses on the SNP (rs11155313, located in the Phactr2 gene) with the lowest P-value in the Tier 2 patient-control series. We employed four case-control series to examine the nominated SNP rs11155313 and identified association in US (OR: 1.39, P=0.032), Canadian (OR: 1.41, P=0.014) and Irish (OR: 1.44, P=0.034) patient-control series, but not in the Norwegian series (OR: 1.15, P=0.27). When combining all four series the observed trend was statistically significant (OR: 1.30, P<0.001). This study shows that reappraisal of publicly available results of GWAS may help nominate new risk factors for PD.
在帕金森病(PD)中复制首个全基因组关联研究(GWAS)的尝试尚未成功识别出遗传风险因素。本研究重新评估了首个GWAS的数据,并聚焦于二级病例对照系列中P值最低的单核苷酸多态性(SNP,rs11155313,位于Phactr2基因)。我们采用了四个病例对照系列来检测指定的SNP rs11155313,并在美国(比值比:1.39,P = 0.032)、加拿大(比值比:1.41,P = 0.014)和爱尔兰(比值比:1.44,P = 0.034)的病例对照系列中发现了关联,但在挪威系列中未发现关联(比值比:1.15,P = 0.27)。当合并所有四个系列时,观察到的趋势具有统计学意义(比值比:1.30,P < 0.001)。本研究表明,对GWAS公开可用结果的重新评估可能有助于确定PD的新风险因素。